Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc covers the period ending February 2015. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific equity transaction and does not contain financial statements or performance metrics.
Material Changes
The filing details a change in the shareholding of Mrs. V. Whyte, a PDMR. On February 11, 2015, she received an award of 11,800 Ordinary Shares under the GlaxoSmithKline 2009 Performance Share Plan. The award was based on a share price of £15.14 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary contingency noted is that the vesting of the awarded shares is subject to meeting performance criteria over a three-year period.
Investor Verification Points
- Verify the vesting schedule and specific performance criteria attached to the 11,800 shares awarded to Mrs. V. Whyte.
- Confirm the total number of shares held by Mrs. V. Whyte post-transaction by reviewing subsequent filings.
- Note that this filing does not reflect the company's overall financial performance for the period.